ACHIEVE-1: orforglipron lowers A1C by 1.3 to 1.6 points in type 2 diabetes, the first Phase 3 readout

Eli Lilly/Orforglipron (Foundayo)

In ACHIEVE-1, Lilly's daily GLP-1 pill orforglipron lowered A1C by 1.3 to 1.6 points over 40 weeks in 559 adults with type 2 diabetes starting near 8% baseline. The drug worked without food restrictions and showed safety matching injectable GLP-1 agents, with 76% of patients reaching the ADA target A1C of <7%.

• Orforglipron lowered A1C by 1.3–1.6 points vs. placebo over 40 weeks.
• 76.2% of patients achieved ADA target A1C <7%; 66% achieved ≤6.5%.
• No food or water restrictions required; taken once daily.
• Early onset of glycemic improvement observed by week 4; published in NEJM June 2025.